CY1112438T1 - Μεθοδος αγωγης της οξειας νεφρικης ανεπαρκειας με διαλυτη θρομβομοδουλινη - Google Patents

Μεθοδος αγωγης της οξειας νεφρικης ανεπαρκειας με διαλυτη θρομβομοδουλινη

Info

Publication number
CY1112438T1
CY1112438T1 CY20111100452T CY111100452T CY1112438T1 CY 1112438 T1 CY1112438 T1 CY 1112438T1 CY 20111100452 T CY20111100452 T CY 20111100452T CY 111100452 T CY111100452 T CY 111100452T CY 1112438 T1 CY1112438 T1 CY 1112438T1
Authority
CY
Cyprus
Prior art keywords
acute renal
soluble
thrombodouline
treatment
renal deficiency
Prior art date
Application number
CY20111100452T
Other languages
English (en)
Inventor
Brian William Grinnell
Thurman Dwight Mckinney
Bruce A Molitoris
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1112438T1 publication Critical patent/CY1112438T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μία μέθοδο για την πρόληψη και/ή την αγωγή ατόμων με οξεία νεφρική ανεπάρκεια προκαλούμενη από μία ποικιλία συνθηκών. Η μέθοδος περιλαμβάνει τη χορήγηση στο άτομο διαλυτής θρομβομοδουλίνης. Σε συνδυασμό με την κλασική φροντίδα, η διαλυτή θρομβομοδουλίνη μειώνει τη βλάβη του ιστού και τη συνεπαγόμενη νοσηρότητα και θνησιμότητα.
CY20111100452T 2005-10-13 2011-05-13 Μεθοδος αγωγης της οξειας νεφρικης ανεπαρκειας με διαλυτη θρομβομοδουλινη CY1112438T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72637605P 2005-10-13 2005-10-13
EP06825898A EP1948216B1 (en) 2005-10-13 2006-10-12 Treatment of acute renal failure with soluble thrombomodulin

Publications (1)

Publication Number Publication Date
CY1112438T1 true CY1112438T1 (el) 2015-12-09

Family

ID=37670944

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100452T CY1112438T1 (el) 2005-10-13 2011-05-13 Μεθοδος αγωγης της οξειας νεφρικης ανεπαρκειας με διαλυτη θρομβομοδουλινη

Country Status (13)

Country Link
US (1) US20080255047A1 (el)
EP (1) EP1948216B1 (el)
JP (1) JP5405829B2 (el)
AT (1) ATE503489T1 (el)
CA (1) CA2625888C (el)
CY (1) CY1112438T1 (el)
DE (1) DE602006021048D1 (el)
DK (1) DK1948216T3 (el)
ES (1) ES2360610T3 (el)
PL (1) PL1948216T3 (el)
PT (1) PT1948216E (el)
SI (1) SI1948216T1 (el)
WO (1) WO2007047430A2 (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2104508A2 (en) * 2006-12-12 2009-09-30 Eli Lilly And Company Treating acute renal failure with soluble thrombomodulin variants
EP2355839A2 (en) * 2008-11-12 2011-08-17 Eli Lilly and Company Compositions and methods of use for soluble thrombomodulin variants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2022713A1 (en) * 1989-08-11 1991-02-12 Nils U. Bang Human thrombomodulin derivatives
EP1449849A3 (en) * 1992-02-05 2006-01-25 Paion Deutschland GmbH Protease-resistant thrombomodulin analog
JP3537440B2 (ja) * 1993-12-17 2004-06-14 持田製薬株式会社 可溶性トロンボモジュリンを長期保存安定化させる方法
WO2004076635A2 (en) * 2003-02-25 2004-09-10 Biovec B.V. Therapeutic applications of thrombomodulin gene via viral and non-viral vectors

Also Published As

Publication number Publication date
WO2007047430A3 (en) 2007-05-24
DK1948216T3 (da) 2011-06-06
US20080255047A1 (en) 2008-10-16
PT1948216E (pt) 2011-05-06
ATE503489T1 (de) 2011-04-15
ES2360610T3 (es) 2011-06-07
WO2007047430A8 (en) 2008-04-10
PL1948216T3 (pl) 2011-10-31
CA2625888A1 (en) 2007-04-26
DE602006021048D1 (de) 2011-05-12
CA2625888C (en) 2015-09-22
EP1948216A2 (en) 2008-07-30
SI1948216T1 (sl) 2011-07-29
WO2007047430A2 (en) 2007-04-26
JP2009511597A (ja) 2009-03-19
JP5405829B2 (ja) 2014-02-05
EP1948216B1 (en) 2011-03-30

Similar Documents

Publication Publication Date Title
DK1809661T3 (da) Humant interferon-beta-mutein
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
ATE551996T1 (de) Behandlung oder prävention von diabetes mit cannabidiol
CY1116160T1 (el) Θεραπεια παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας
ATE548035T1 (de) Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
HRP20110969T1 (en) Pimobendan to be used for the reduction of heart size in mammals suffering from heart failure
BRPI0508403A (pt) produtos de pelìcula tendo propriedades de desintegração controlada
EA201290041A1 (ru) Лечение расстройств, связанных с макрофагами
MA33043B1 (fr) Inhibiteur sglt-2 pour le traitement du diabete sucre de type 1, du diabete sucre de type 2, d'une intolerance au glucose ou d'une hyperglycemie
EA201000563A1 (ru) Триазолпиридиновые ингибиторы 11-бета- гидроксистероид - дегидрогеназы типа i
EA200701995A1 (ru) Способы уменьшения кальцификации
SMT201200014B (it) Nalmefene cloridrato diidrato.
EA201100756A1 (ru) Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенным профилем безопасности по сравнению со стандартным лечением варфарином
SV2006002296A (es) Tratamiento de mastitis ref. bhc041335-sv
RU2007122391A (ru) S-миртазапин для лечения приливов
DK1843771T3 (da) Anvendelse af pyrimidylaminobenzamider til behandling af sygdomme, der responderer på modulation af Tie-2-kinase-aktiviteten
CY1112438T1 (el) Μεθοδος αγωγης της οξειας νεφρικης ανεπαρκειας με διαλυτη θρομβομοδουλινη
EP2754447A3 (en) Treating acute renal failure with soluble thrombomodulin variants
ITMI20040954A1 (it) Derivati del 3,6-diazabiciclo 3.1.i.eptano ad attivita' analgesica
ATE465741T1 (de) 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
EA200801678A1 (ru) Применение производных триазина для производства лекарственного средства, обладающего заживляющим или ангиогенным эффектом
DK1880727T3 (da) Topisk vaginal farmaceutiske sammensætninger
TN2011000206A1 (en) Compositions and methods of use soluble thrombomodulin variants
ATE454144T1 (de) Behandlung von malignen neoplasien
TW200640484A (en) Treatment of brain tissue damage